Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01735071

Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer

Ovarian Epithelial Cancer Recurrent Clinical Trial

Official title:
Multicenter, Randomized, Non-comparative, Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.

Clinical Trial Summary

This study is aimed at assessing the efficacy and the safety of the combination of bevacizumab and trabectedin with or without carboplatin in adult women with epithelial ovarian cancer at first recurrence occurred 6-12 months after the end of the last (first or second) platinum-containing regimen. According to the Bryant and Day design the primary endpoints will be the proportion of progression-free patients at 6 months for the efficacy, and the proportion of patients with severe toxicity for the safety at the same time-point.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01735071
Study type Interventional
Source Mario Negri Institute for Pharmacological Research
Contact
Status Completed
Phase Phase 2
Start date July 2013
Completion date March 18, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT01899599 - PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer Phase 2
Active, not recruiting NCT01715168 - A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer Phase 1
Completed NCT02394015 - Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Completed NCT01588964 - IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer Phase 2
Completed NCT02026921 - A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer Phase 2
Completed NCT02260544 - Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection Phase 1
Active, not recruiting NCT01611766 - Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? Phase 3
Completed NCT02735928 - Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor N/A
Completed NCT02014337 - Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Phase 1
Active, not recruiting NCT01376752 - Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment Phase 3